XOMA Royalty (NASDAQ:XOMA) Raised to Hold at TD Cowen

XOMA Royalty (NASDAQ:XOMA) was upgraded by investment analysts at TD Cowen to a “hold” rating in a note issued to investors on Friday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. UBS Group set a $76.00 target price on XOMA Royalty in a report on Tuesday, December 9th. Finally, Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.60.

XOMA Royalty Price Performance

Shares of NASDAQ:XOMA opened at $24.01 on Friday. The business’s 50 day simple moving average is $26.44 and its 200-day simple moving average is $31.11. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91. The firm has a market capitalization of $297.24 million, a price-to-earnings ratio of 32.45 and a beta of 0.86. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%.The business had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. As a group, equities analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Owen Hughes acquired 100,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the transaction, the chief executive officer directly owned 102,000 shares in the company, valued at $2,555,100. This trade represents a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On XOMA Royalty

A number of hedge funds have recently made changes to their positions in XOMA. Stonepine Capital Management LLC grew its holdings in shares of XOMA Royalty by 17.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after acquiring an additional 22,330 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at $370,000. Panagora Asset Management Inc. acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at $463,000. Man Group plc purchased a new position in XOMA Royalty in the 3rd quarter worth about $247,000. Finally, BNP Paribas Financial Markets raised its holdings in XOMA Royalty by 266.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,346 shares during the period. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.